A platform of integrative studies from in vitro to in vivo experiments: towards drug development for ischemic retinopathy.

Abstract

Pathologic angiogenesis induced by hypoxia is a hallmark of ischemic retinopathy including diabetic retinopathy and retinopathy of prematurity. These 2 diseases affect substantial number of working population and preterm babies, respectively, resulting in visual deterioration. It is essential for novel therapeutics for ischemic retinopathy to demonstrate the potency in reducing pathologic angiogenesis and the safety without definite toxicity on the retina and the whole body. In this review, we suggest a novel platform of integrative studies from in vitro to in vivo experiments on angiogenesis and toxicity with the aim of accelerating and facilitating the development of novel therapeutic agents for ischemic retinopathy. Robust in vitro and in vivo studies with bridging microfluidic and ex vivo systems help researchers to evaluate the efficacy and anticipate the toxicity of candidate drugs. We hope that novel therapeutic approach based on this platform will be developed in near future and reduce the incidence of vision loss from ischemic retinopathy.

• Authors: Dong Hyun Jo, Jin Hyoung Kim, Jeong Hun Kim
• Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (Biomed Pharmacother) Vol. 69 Pg. 367-73 (Feb 2015) ISSN: 1950-6007 [Electronic] France
• PMID: 25661384 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
• Copyright: Copyright © 2014 Elsevier Masson SAS. All rights reserved.

Topics

• Animals
• Disease Models, Animal
• Drug Discovery
• Drug Evaluation, Preclinical
• Humans
• Ischemia (drug therapy)
• Neovascularization, Pathologic (drug therapy)
• Retinal Diseases (drug therapy)